Related Experiment Videos
Solid-phase total synthesis of polymyxin B1.
S K Sharma1, A D Wu, N Chandramouli
1Oncology Department, Novartis Institute of Biomedical Research, Summit, NY 07901-1398, USA. SUSHIL.SHARMA@PHARMA.NOVARTIS.COM
Summary
Researchers achieved the total solid-phase synthesis of polymyxin B1, a complex peptide antibiotic. This method offers a viable route for producing this vital compound, demonstrating high yield and purity.
Area of Science:
- Organic Chemistry
- Medicinal Chemistry
- Biotechnology
Background:
- Polymyxin B1 is a critical antibiotic used to treat severe bacterial infections.
- The complex macrocyclic structure of polymyxin B1 presents significant synthetic challenges.
- Existing methods for polymyxin B1 production are often inefficient or difficult to scale.
Purpose of the Study:
- To develop a robust and efficient total solid-phase synthesis of polymyxin B1.
- To demonstrate the feasibility of synthesizing complex peptide macrocycles using solid-phase techniques.
- To provide a reliable method for producing high-purity synthetic polymyxin B1.
Main Methods:
- Utilized solid-phase synthesis methodology.
- Employed the orthogonal protecting group N-1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl (Dde).
- Analyzed the synthetic peptide using Mass Spectrometry (MS) and High-Performance Liquid Chromatography (HPLC).
Main Results:
- Successfully achieved the total solid-phase synthesis of polymyxin B1.
- Obtained a 20% yield for the synthetic polymyxin B1.
- Confirmed the identity and purity of the synthetic peptide, matching the naturally occurring antibiotic via MS and HPLC analysis.
Conclusions:
- The developed solid-phase synthesis is effective for producing complex peptide macrocycles like polymyxin B1.
- This method offers a high-yield and high-purity route to synthetic polymyxin B1.
- The synthetic polymyxin B1 is indistinguishable from the natural antibiotic, validating the synthesis approach.